Mutations of the FLT3, c-KIT, c-FMS, KRAS, NRAS, BRAF and CEBPA genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal-transduction pathway are frequent in acute myeloid leukemia (AML). We examined 140 patients with therapy-related myelodysplasia or AML (t-MDS/t-AML) for point mutations of these seven genes. In all, 11 FLT3, two c-KIT, seven KRAS, eight NRAS and three BRAF mutations were identified in 29 patients (21%). All but one patient with a FLT3 mutation presented with t-AML (P ¼ 0.0002). Furthermore, FLT3 mutations were significantly associated with previous radiotherapy without chemotherapy (P ¼ 0.03), and with a normal karyotype (P ¼ 0.004), but inversely associated with previous therapy with alkylating agents (P ¼ 0.003) and with À7/7qÀ (P ¼ 0.001). RAS mutations were associated with AML1 point mutations (P ¼ 0.046) and with progression from t-MDS to t-AML (P ¼ 0.008). Noteworthy, all three patients with BRAF mutations presented as t-AML of M5 subtype with t(9;11)(p22;q23) and MLL-rearrangement (P ¼ 0.01). In t-AML RAS/BRAF mutations were significantly associated with a very short survival (P ¼ 0.017). Half of the patients with a mutation in the RTK/RAS-BRAF signal-transduction pathway (denoted 'class-I' mutations) simultaneously disclosed mutation of a hematopoietic transcription factor (denoted 'class-II' mutations) (P ¼ 0.046) suggesting their cooperation in leukemogenesis.
Introduction
Mounting experimental and in vivo evidence suggests that the molecular pathogenesis of AML requires cooperating mutations of at least two classes of genes, recently denoted as 'class-I' and 'class-II' mutations. 1, 2 Class-I mutations constitutively activate genes in the kinase signalling pathways such as FLT3, c-KIT, c-FMS, RAS and BRAF, whereas class-II mutations inactivate hematopoietic transcription factors such as AML1, CBFb, MLL and RARa. Together class-I and class-II mutations enhance proliferation, immortalize and block differentiation of hematopoietic progenitor cells, the hallmark of neoplastic transformation. 1, 2 The FLT3, c-KIT and c-FMS genes encode membrane-bound class III receptor tyrosine kinases (RTK's) and are important mediators of mitogenic signal transduction. [3] [4] [5] [6] FLT3 mutations are observed in 30% of patients with AML de novo, mainly cases with normal cytogenetics or t (15;17) . 4, 5, [7] [8] [9] [10] Two types of FLT3 mutations have been identified: internal tandem duplications (FLT3/ITD) of the juxtamembrane domain in 20-25% of AML patients, and activating loop mutations (FLT3/ALM) in the cytoplasmatic tyrosine kinase domain (TKD) in 5-10%. 11 Activating c-KIT or c-FMS mutations are observed in 5-10% of AML de novo, frequently cases with t(8;21) or inv (16) . 12, 13 The activated RTK's exert their downstream effects through the intracellular RAS/RAF/MEK/ERK/MAP kinase pathway. [4] [5] [6] Mutations of the three RAS genes: HRAS, KRAS and NRAS are frequent in human neoplasia. 14 In MDS and AML de novo, KRAS or NRAS mutations are detected in 15-25% of the patients, whereas HRAS mutations are very rare. [15] [16] [17] Recently, mutations of BRAF, a serine/threonine kinase isoform of RAF and a downstream intermediate of the RAS-signalling pathway, were identified in 66% of patients with multiple myeloma. 18 BRAF mutations were subsequently detected in a few cases of AML de novo. 19 Like mutant RAS, mutant BRAF proteins constitutively activate the RAS/BRAF-signalling pathway. 14, 18, 20 The CEBPA gene encodes the hematopoietic transcription factor CCAAT/enhancer binding protein-alpha (C/EBPa) which is a downstream effector of the RTK/RAS-BRAF-signal transduction pathway. 21 Recently, dominant-negative mutations of CEBPA were identified in 10% of patients with AML de novo, most commonly in cases of the M1 or M2 subtype with normal cytogenetics. [22] [23] [24] Taken together mutations of the FLT3, c-KIT, c-FMS, KRAS, NRAS, BRAF or CEBPA genes are observed in more than 50% of patients with AML de novo. A study of these mutations is of clinical importance, particularly in patients classified in the intermediate risk group of AML with normal cytogenetics. Whereas FLT3 mutations in this risk group are associated with a poor prognosis, [8] [9] [10] 25 CEBPA mutations imply a favorable outcome. 24, 26, 27 The prognostic significance of RAS mutations remains controversial, 15, 25, 28 and it is unknown for c-KIT or BRAF mutations. Mutation analysis of all seven genes could improve our understanding of their mutual role in the multistep development of MDS and AML. 16, 17 Therapy-related AML, often presenting as t-MDS, is the most serious long-term complication of current cancer therapy. The disease is most often associated with previous treatment with alkylating agents or topoisomerase II inhibitors, but many patients have also received radiotherapy, in a small subgroup as the only treatment. The molecular biology of the disease differs according to etiology, and seems to follow specific genetic pathways associated with characteristic chromosome aberrations. [29] [30] [31] [32] To further establish the significance of mutated genes in the different genetic pathways of t-MDS and t-AML, and if possible to relate gene mutations to specific types of mutagenic therapy, we examined our total series of 140 patients with t-MDS or t-AML and available DNA for mutations of FLT3, c-KIT, c-FMS, KRAS, NRAS, BRAF and CEBPA.
Patients, materials and methods

Patients
A total of 89 unselected patients presenting with t-MDS and 51 unselected patients presenting with overt t-AML, all studied previously for AML1 mutations, 33 were included in the present study. In all, 81 of these patients have previously been studied for FLT3/ITD.
FLT3, c-KIT, c-FMS, KRAS, NRAS BRAF, C/EBPa mutation analysis
Genomic DNA was extracted with the TRIzol reagent or with the DNAzol reagent (GIBCO Life Technologies, Grand Island, NY, USA). The FLT3/ITD mutation analysis was performed by PCR amplification of exons 14 and 15 (previously incorrectly numbered as exons 11 and 12) , and mutations were detected by agarose gel electrophoresis as reported.
34 FLT3/ALM mutation analysis of codons D835 and I836 was performed by PCR amplification of exon 20 followed by restriction fragment length polymorphism (RFLP) analysis of the PCR product using the EcoRV restriction endonuclease (New England Biolabs, Frankfurt, Germany) as originally described.
11
Screening for mutations was restricted to exons 8 and 17 of c-KIT, exons 11 and 22 of c-FMS, exons 1 and 2 of KRAS and NRAS and exons 11 and 15 of BRAF. Mutation analysis was performed by PCR amplification followed by single stranded conformation polymorphism analysis of the PCR amplimers (PCR-SSCP) at 4, 12 and/or 201C as described. 35 The intronic primers (DNA Technology, Aarhus, Denmark) are listed in Supplementary Table 1 . PCR reaction and amplification conditions were as described. 33 The entire coding region of CEBPA was subjected to direct sequencing. Two PCR fragments were amplified from each patient using the same primers as Pabst et al. 22 PCR reaction and amplification conditions were as above, except for the inclusion of a 5% final concentration of DMSO and an annealing temperature of 621C.
Aberrantly migrating bands of FLT3 and SSCP bands of c-KIT, c-FMS, KRAS, NRAS and BRAF were reamplified, purified and subjected to bidirectional sequencing using BigDye terminator sequencing kit (Applied Biosystems) and analyzed on the ABI PRISM 310 or 3100 Genetic Analyser's (Applied Biosystems, Foster City, CA, USA) as reported. 33 
Results
FLT3/ITD and FLT3/ALM
A total of 11 of 140 patients (8%) with t-MDS/t-AML disclosed heterozygous FLT3 mutations including three cases (nos 64, 105, and R) reported in our previous study 34 (Table 1 , Figure 1a) . Nine patients showed an FLT3/ITD only, one patient showed an FLT3/ ALM only, whereas one patient presented two FLT3 mutations: one FLT3/ITD and one FLT3/ALM ( Table 2 ). The 10 FLT3/ITD were shown by sequencing to be in-frame duplications of various lengths of the tyrosine-rich stretch in the juxtamembrane domain of FLT3 (data not shown). Sequencing of the two ALM disclosed a three-base pair deletion 2508-2510delCAT predicted to result in a amino-acid deletion I836del in case 105, and a missense mutation 2503G4T predicted to result in a amino-acid substitution D835Y in case 178.
c-KIT mutations
In all, 14 of the 140 patients examined for c-KIT mutations disclosed aberrantly migrating SSCP bands of exon 17. Bidirectional sequencing disclosed a heterozygous missense mutation 2447A4T predicted to result in a D816V in patients 95 and 126 (Table 1, Figure 1b) . The other 12 cases all showed a heterozygous 2394C4A at codon 798, which, because it is silent, most likely represents a single nucleotide polymorphism (SNP).
c-FMS mutations
Aberrantly migrating bands of c-FMS exon 22 were observed in 44 of the 140 patients. Direct sequencing showed CA4TC double nucleotide substitution in six patients and C4T substitution in another 38 patients. Both types of substitutions were located 34 bases downstream of the TGA stop codon and most likely represent SNP's. No other abnormalities were observed.
RAS mutations
Aberrantly migrating SSCP bands of KRAS or NRAS were observed in 14 of the 140 patients (10%) (Table 2, Figure 1c -f). Bidirectional sequencing of reamplified PCR products from these 14 cases disclosed a single, heterozygous RAS mutation in 13 cases, whereas two different RAS mutations were observed in case 27 (Table 3 ). This patient showed one mutation at codon 12 and another at codon 13 of KRAS, by sequencing shown to be either biallelic mutations or independent mutations in different subclones. The RAS mutations included three mutations at codon 12, one mutation at codon 13 and four mutations at codon 61 of NRAS; four mutations at codon 12, one mutation at codon 13 and one mutation at codon 61 of KRAS. The mutational spectrum consisted of eight G4A transitions, one A4G transition, four A4T transversions, one G4T transversion and one G4C transversion.
BRAF mutations
Three of the 140 patients (cases 66, 127 and P) showed aberrantly migrating SSCP bands of BRAF exon 15 (Table 2, Figure 1g ). Reamplification and bidirectional sequencing of the PCR product showed a heterozygous 1799T4A predicted to result in an amino-acid substitution (V600E) in all three patients. This substitution represents the hot spot for mutation in the kinase domain of BRAF.
18 In case no. 66 with a KRAS as well as a BRAF mutation, interphase FISH 33 using the LSI MLL Dual Color Probe (Vysis, Downers Grove II, USA) showed the t(9;11) translocation in 189 of 200 cells examined (95%). Subcloning of PCR fragments with the KRAS or the BRAF mutation, and subsequent SSCP of independently picked clones showed that the mutated KRAS allele was present in four seven of 20 clones (35%), and that the mutated BRAF allele was present in only four of 20 clones (20%). This low percentage corresponds with the relatively faint SSCP bands of mutated KRAS in Figure 1c and of mutated BRAF in Figure 1g . Thus the KRAS and the BRAF mutations may be present in two different leukemic subclones both carrying the t(9;11) translocation.
CEBPA mutations
Mutations of the CEBPA gene were not detected by direct sequencing of the entire coding region in any of the 96 patients FLT3 mutations related to clinical, cytogenetic and genetic characteristics FLT3 mutations were significantly associated with previous treatment with radiotherapy only (P ¼ 0.03) with presentation of the disease as overt t-AML (P ¼ 0.0002) and with a normal karyotype (P ¼ 0.004) ( Table 3 ). An inverse association was observed to previous therapy with alkylating agents (P ¼ 0.003), to À7/7qÀ (P ¼ 0.001) and to a complex karyotype (P ¼ 0.05) ( Table 3 ). In patients with FLT3 mutations presenting with t-AML, all associations remained significant (data not shown, Supplementary Tables 2 and 3 ).
RAS mutations related to clinical, cytogenetic and genetic characteristics
Patients with RAS mutations did not show significant clinical or cytogenetic associations when compared to patients with normal RAS, except for a highly significant association to leukemic progression from t-MDS to t-AML (P ¼ 0.008, Table 4 ). The only patient with a RAS mutation not transforming (case 156) survived for only 4 months (Table 2 ). However, 36% of patients with RAS mutations had a normal karyotype and 21% presented with t-AML of FAB subtype M5. RAS mutations were significantly associated with AML1 point mutations (P ¼ 0.046, Table 4 ). This association remained significant among the 89 patients presenting with t-MDS (P ¼ 0.043).
Mutations in the RTK/RAS-BRAF-signalling pathway related to clinical and cytogenetic characteristics
Mutations in the RTK/RAS-BRAF pathway were significantly associated with presentation of the disease as t-AML (P ¼ 0.00002), with the M5 FAB subtype (P ¼ 0.006), with a normal karyotype (P ¼ 0.002), with recurrent balanced translocations (P ¼ 0.025) and with previous treatment with radiotherapy only (P ¼ 0.049), but negatively associated with presentation of the disease as RA þ RARS (P ¼ 0.001), with À7/ 7qÀ (P ¼ 0.0001) and with a complex karyotype (P ¼ 0.01) ( Table 5) .
The median latency from start of treatment for primary disease to development of t-MDS or t-AML was significantly shorter for patients with mutations than for patients without mutations in the RTK/RAS-BRAF pathway (P ¼ 0.027) ( Table 5 ). This association was mainly caused by the very short latency of the 16 patients with RAS/BRAF mutations (P ¼ 0.018, Wilcoxon twosample test, two-sided, data not shown).
The patients with mutations in the RTK/RAS-BRAF pathway showed a nonsignificantly shorter survival than the patients without such mutations (P ¼ 0.19, Table 5 ). In t-AML, however, nine patients with RAS/BRAF mutations had a significantly shorter survival than the 42 patients without RAS/BRAF mutations (median 1 month vs 6.5 months, P ¼ 0.017, log rank test, two-sided). All three patients with BRAF mutations survived for only 1 month (Tables 2 and 5 ).
Cooperating mutations in t-MDS and t-AML
FLT3, c-KIT, RAS and BRAF mutations were almost mutually exclusive, as only one of the 29 patients (case 66) had concomitant mutations of two different genes: KRAS and BRAF. P t . 2 9 P t . 1 2 P t . 2 7 P t . 6 6 P t . 9 3 P t . 3 5 P t . 3 6 P t . 4 6 P t . 6 6 P t . p P t . 4 5 P t . 1 1 6 P t . 1 0 7 P t . 1 2 7 P t . 1 3 6 P t . 1 3 2 P t . 4 7 P t . 5 1 P t . 9 5 P t . 5 2 P t . Figure 1 Detection of mutation in the RTK/RAS-BRAF signal transduction pathway. FLT3/ITD mutations were detected by PCR amplification and agarose gel electrophoresis (a). c-KIT mutations (b), KRAS mutations in exon 1 (c) and exon 2 (d), NRAS mutations in exon 1 (e) and exon 2 (f) and BRAF mutations (g) were detected by PCR/SSCP. Reamplification and bi-directional sequencing confirmed and characterized all mutations. Pt. denotes patient number.
Mutations of genes in the receptor tyrosine kinase DH Christiansen et al In all, 14 of the 29 patients with mutation in the RTK/RAS-BRAF pathway (class-I mutations) had point mutations or chimeric rearrangements of the hematopoietic transcription factor genes AML1, MLL or RARa (class-II mutations) as compared to only 31 of 111 patients without mutations of FLT3, c-KIT, RAS or BRAF (P ¼ 0.046, Table 6 ). This was mainly caused by the close association between RAS/BRAF mutations and class-II mutations (10 of 16 patients with RAS/BRAF mutations vs 35 of 124 patients without RAS/BRAF mutations showed class-II mutations (P ¼ 0.009, Table 6 )). Despite the small number of patients, a significant association was observed between RAS/BRAF mutations and chimeric rearrangements of MLL (five of 16 patients with RAS/BRAF mutations vs six of 124 patients without RAS/BRAF mutations presented MLL-rearrangements; P ¼ 0.003, Table 6 ). In t-AML, three of five patients with t(9;11) vs 0 of 46 patients without t(9;11) disclosed BRAF mutations (P ¼ 0.0005, Fishers exact test, two-sided).
Discussion
The present study disclosed mutations of the FLT3, c-KIT, KRAS, NRAS or BRAF genes in the RTK/RAS-BRAF signal transduction pathway in 21 of 51 patients presenting with t-AML (41%) and in eight of 89 patients presenting with t-MDS (8%) (P ¼ 0.00002, Table 5 ). Mutations of the five genes were mutually exclusive (except in case 66) confirming previous findings in patients with AML de novo. 16, 17 Recent evidence suggests a cooperation between class-I and class-II mutations in leukemogenesis.
1,2 Chimeric rearrangement of RARa has been associated with FLT3 mutations in acute promyelocytic leukemia, 4, 5, [8] [9] [10] and chimeric rearrangements of AML1 or CBFb have been associated with c-KIT mutations in core binding factor leukemias. 11, 12 A recent study 39 showed a significant association between FLT3/ITD and AML1 point mutations in patients with AML of M0 subtype. Our results support these findings ( Table 6 ). As many genetic abnormalities in t-MDS and t-AML remain to be identified cooperation between the two classes of mutations may be even more frequent than demonstrated in the present study.
Few BRAF mutations have so far been detected in de novo AML. 19, 37 Although the number of cases is small, our study is the first to demonstrate a highly significant association between BRAF/V600E mutations and t(9;11) translocation in t-AML. Moreover, another of the five patients with t(9;11) showed a FLT3/D835 mutation (Table 1) . These results suggest that BRAF/V600E and FLT3/ALM mutations are frequent in MLL-AF9 mediated leukemogenesis. 38 In agreement with this notion, a recent study found FLT3/ALM mutations in eight of 44 with MLLmediated infant ALL. 39 The very short latency and the very poor survival particularly of patients with concomitant MLL-AF9 and BRAF mutations (Tables 2 and 5) suggests that few additional genetic mutations are required to trigger this apparently very aggressive subtype of overt t-AML. 38 As one patient (case 66) showed KRAS and BRAF mutations in only 35 and 20%, respectively, of monoblasts with the t(9;11) translocation, these class-I mutations could be present in two different leukemic subclones and represent subsequent genetic events in MLL-AF9 mediated t-AML. 38, 40 A similar association has been suggested for FLT3/D835-I836 mutations in MLL-mediated infant ALL 39 and for BRAF mutations in melanoma. 41 Large prospective studies are needed to elucidate these associations. However, analogous with recent findings of a critical function of BRAF in myelopoesis, 42 our results suggests that BRAF mutations are important in the pathogenesis of specific AML FAB subtypes. Table 5 Clinical and cytogenetic characteristic of 140 patients with t-MDS or t-AML with and without activating mutations in the RTK/RAS-BRAF pathway Log rank test, two-sided.
Table 6
Association between class-I and class-II mutations in 140 patients with t-MDS and t-AML In solid tumors and AML de novo, RAS mutations have been associated with previous genotoxic exposure. 43 Smoking-and smoky coal-associated lung tumors show a high frequency of G4T transversions at codon 12 of KRAS. 44 Exposure to alkylating agents has been associated with G4A or C4T transitions in experimental systems. 45 The G4A transition observed in 53% of our patients with RAS mutations was not associated with previous treatment with any specific type of alkylating agent. A recent study showed a highly significant association between KRAS/NRAS mutations and previous radiotherapy and/or chemotherapy in AML. 46 Six of seven patients with t-AML had RAS mutations, and five of these six cases had two RAS mutations. Our findings do not confirm these results ( Table 2 ) as only 10% of our patients showed RAS mutations, and only one of 14 patients showed two concurrent RAS mutations.
Considering clinical characteristics as type of previous therapy, the latent period to development of t-MDS or t-AML and the cytogenetic characteristics of cases with FLT3 and RAS mutations, 16 of 25 patients presented at least one uncharacteristic finding. Thus, six of 25 patients had received radiotherapy only (cases 29, 35, 52, 107, 131 and 148). In our total series, only 17 of 140 patients with t-MDS or t-AML had received radiotherapy only. FLT3 and RAS mutations were not associated with any specific type of chemotherapy, in fact FLT3 mutations showed negative association to previous treatment with alkylating agents. Extremely short latent periods were observed for cases 35, 52 and 136 and extremely long latent periods were observed for cases 107 and 131. Uncommon cytogenetic characteristics were observed for cases 27, 29, 35, 36, 46, 47, 51, 52, 105, 132, 136, 148, 156 and R, including 11 patients presenting a normal karyotype. These findings all raise the question whether many of these leukemias and their gene mutations could have developed spontaneously, unrelated to previous therapy with alkylating agents and topoisomerase II inhibitors. Some leukemias, in particular those with FLT3 mutations, could alternatively have been induced by radiotherapy. The positive association between FLT3 mutations and previous radiotherapy, if confirmed in larger studies, is of interest, as radiotherapy has not previously been linked to specific genetic abnormalities in t-MDS or t-AML.
Based on clinical, cytogenetic and genetic characteristics, we have discussed different genetic pathways of t-MDS and t-AML. 31 Pathways I and II included mainly patients treated with alkylating agents and presenting as t-MDS. Pathway I was cytogenetically characterized by À7/7qÀ but normal chromosomes 5, whereas pathway II was characterized by À5/5q with or without abnormalities of chromosome 7, often with a complex karyotype. Genetically, pathway I was associated with a high frequency of heterozygous AML1 point mutations 34 and hypermethylation of p15, 47 whereas pathway II was characterized by a high frequency of p53 mutations 36 and amplification or duplication of MLL 48 and AML1. 49 The next three pathways included patients characteristically treated with topoisomerase II inhibitors and presenting as overt t-AML with the recurrent balanced chromosome translocations leading to chimeric rearrangements of one of the genes MLL, AML1, CBFb, RARa or NUP98. The last two pathways included patients with t-MDS and t-AML and a normal karyotype or patients with cytogenetic abnormalities not observed recurrently in t-MDS or t-AML. Patients in the last two pathways had not received a characteristic type of therapy for their primary disease. FLT3 mutations seem to cluster in the pathway with a normal karyotype presenting as overt t-AML. RAS/BRAF mutations seem in overt t-AML to cluster in the pathway defined by chimeric rearrangement of MLL, whereas RAS mutations in t-MDS are associated with AML1 point mutations.
AML1 point mutations were recently associated with progression of t-MDS to t-AML. 33 In the present study, 86% of the patients presenting with t-MDS and RAS mutations subsequently progressed to overt t-AML. Thus both types of mutations could be directly involved and perhaps cooperate in leukemic transformation.
The many significant associations require confirmation by further studies. Although 140 patients with t-MDS or t-AML were studied, the clinical, cytogenetic and genetic subgroups were often small. Our results, however, emphasize, that t-MDS and t-AML as their de novo counterparts from an etiological, pathogenic and clinical point of view are heterogeneous diseases, and that extrapolation from therapy-related to de novo diseases may improve our understanding of leukemogenesis.
